Literature DB >> 15701203

Focus on topiramate in neuropathic pain.

Jean G Dib1.   

Abstract

Topiramate is a drug that has shown efficacy in the treatment of epilepsy. A survey of MEDLINE, EMBASE and the American Academy of Neurology Abstracts reveals there is now evidence that topiramate is also effective in the treatment of neuropathic pain. The dose that has been studied ranges from 25 mg to 800 mg with a suggested dose of 400 mg daily. However, further randomized, double blind studies are needed to confirm this new use of topiramate and explore the proper dose and mechanism of action. Topiramate is conspicuous amongst the antiepileptic drugs for being well tolerated and having fewer drug interactions. Thus, it might offer an advantage over such drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15701203     DOI: 10.1185/030079904X11358

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  Improvement of cervico-trunco-brachial segmental dystonia with topiramate.

Authors:  Spiridon Papapetropoulos; Carlos Singer
Journal:  J Neurol       Date:  2005-11-22       Impact factor: 4.849

2.  Topiramate and cortical excitability in humans: a study with repetitive transcranial magnetic stimulation.

Authors:  M Inghilleri; F Gilio; A Conte; V Frasca; C Marini Bettolo; E Iacovelli; B Gregori; M Prencipe; A Berardelli
Journal:  Exp Brain Res       Date:  2006-08-05       Impact factor: 1.972

3.  Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial.

Authors:  Surena Nazarbaghi; Mohammad Reza Amiri-Nikpour; Aynaz Foroughi Eghbal; Rohollah Valizadeh
Journal:  Electron Physician       Date:  2017-10-25

4.  Efficacy of zonisamide in migraineurs with nonresponse to topiramate.

Authors:  Jin-Young Chung; Min-Wook Kim; Manho Kim
Journal:  Biomed Res Int       Date:  2014-07-02       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.